Artiva Investigational Site Phoenix

The trials here

What the trial at this site is about, from its registry record.

Conditions

• Dermatomyositis and polymyositis (myositis)
• Rheumatoid arthritis
• Sjögren's disease
• Systemic sclerosis (scleroderma)

Running trials

• Recruiting

  AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

  NCT06991114· Phase 2· Artiva Biotherapeutics, Inc.· Source

  Contact: Chanel Mansfield Director, Clinical Operations, MPH

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Dermatomyositis and polymyositis (myositis)1 recruiting
• Rheumatoid arthritis1 recruiting
• Sjögren's disease1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting